143 related articles for article (PubMed ID: 38647164)
1. Access in all areas? a round up of developments in market access and health technology assessment: part 4.
Beattie A; Treharne C; Ramagopalan SV
J Comp Eff Res; 2024 Jun; 13(6):e240060. PubMed ID: 38647164
[TBL] [Abstract][Full Text] [Related]
2. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
3. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
4. Do France, Germany, and Italy agree on the added therapeutic value of medicines?
Casilli G; Lidonnici D; Jommi C; De Nigris M; Genazzani AA
Int J Technol Assess Health Care; 2023 Aug; 39(1):e54. PubMed ID: 37580971
[TBL] [Abstract][Full Text] [Related]
5. [Policy developments of health technology assessment in the European Union].
Baran-Kooiker A; Czech M; Hołownia-Voloskova M
Postepy Biochem; 2019 Nov; 65(4):319-321. PubMed ID: 31945287
[TBL] [Abstract][Full Text] [Related]
6. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
Russo P; Mennini FS; Siviero PD; Rasi G
Ann Oncol; 2010 Oct; 21(10):2081-2087. PubMed ID: 20335370
[TBL] [Abstract][Full Text] [Related]
7. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
8. Access in all areas? A round up of developments in market access and health technology assessment: part 1.
Gilardino R; Treharne C; Mardiguian S; Ramagopalan SV
J Comp Eff Res; 2023 Oct; 12(10):e230129. PubMed ID: 37584405
[TBL] [Abstract][Full Text] [Related]
9. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2022 May; 11(7):473-475. PubMed ID: 35261285
[TBL] [Abstract][Full Text] [Related]
10. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
11. Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
Giuliani G; Chassagnol F; Traub D; Gyldmark M; Hebborn A; Ducournau P; Ruof J
Health Econ Rev; 2018 Sep; 8(1):24. PubMed ID: 30242522
[TBL] [Abstract][Full Text] [Related]
12. The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.
Vreman RA; van Hoof D; Nachtnebel A; Daems J; van de Casteele M; Fogarty E; Adams R; Timmers L
Int J Technol Assess Health Care; 2023 Jun; 39(1):e44. PubMed ID: 37317832
[TBL] [Abstract][Full Text] [Related]
13. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
Al-Omar HA; Alghannam HH; Aljuffali IA
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
[TBL] [Abstract][Full Text] [Related]
14. The role of health technology assessment bodies in shaping drug development.
Ciani O; Jommi C
Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
[TBL] [Abstract][Full Text] [Related]
15. Access in all areas? A round up of developments in market access and health technology assessment: part 3.
Beattie A; Treharne C; Ramagopalan SV
J Comp Eff Res; 2024 Mar; 13(3):e240009. PubMed ID: 38329446
[TBL] [Abstract][Full Text] [Related]
16. The burden of rheumatoid arthritis and access to treatment: determinants of access.
Lundqvist J; Kastäng F; Kobelt G; Jönsson B
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
[TBL] [Abstract][Full Text] [Related]
17. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
18. Access in all areas? A round up of developments in market access and health technology assessment: part 2.
Beattie A; Treharne C; Mardiguian S; Ramagopalan SV
J Comp Eff Res; 2023 Dec; 12(12):e230162. PubMed ID: 37916681
[TBL] [Abstract][Full Text] [Related]
19. "Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.
Vogler S
Ger Med Sci; 2022; 20():Doc05. PubMed ID: 35465640
[No Abstract] [Full Text] [Related]
20. Need for redesigning pharmacologic research in older individuals. A position statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA).
Bernabei R; Caputi A; Di Cioccio L; Fini M; Gallo PF; Marchionni N; Marrocco W; Melchiorri D; Mugelli A; Pilotto A; Rasi G; Zuccaro SM
J Gerontol A Biol Sci Med Sci; 2011 Jan; 66(1):66-7. PubMed ID: 20980360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
